美国食品和药物管理局批准使用Cosentyx治疗严重状腺炎的青少年. FDA approves Cosentyx for teens with severe hidradenitis suppurativa.

美国食品和药物管理局批准secokinumab (Cosentyx) 适用于中度至重度上腺炎的12岁及以上的青少年,使其成为第一个批准用于这一年龄组的IL-17A抑制剂. The FDA has approved secukinumab (Cosentyx) for adolescents aged 12 and older with moderate-to-severe hidradenitis suppurativa, making it the first IL-17A inhibitor approved for this age group. 根据成人试验数据、制药动能建模和其他条件下的儿科研究,这项批准支持至少30公斤重的病人按重量服药。 The approval, based on adult trial data, pharmacokinetic modeling, and pediatric studies for other conditions, supports weight-based dosing for patients weighing at least 30 kg. 该药物已经用于几种自发免疫疾病,它为慢性皮肤疾病提供了一种新的生物治疗选择,这种慢性皮肤疾病造成疼痛、疤痕和生活质量下降。 The drug, already used for several autoimmune diseases, offers a new biologic treatment option for a chronic skin condition that causes pain, scarring, and reduced quality of life.